Rheoscience A/S and Dr. Reddy's Laboratories, Inc.'s Commence the First Phase III Trial of Balaglitazone (DRF 2593)

COPENHAGEN, Denmark & HYDERABAD, India--(BUSINESS WIRE)--Rheoscience A/S and Dr. Reddy’s Laboratories (NYSE:RDY) today announced that the first patient has been dosed in a Phase III study with Balaglitazone (DRF2593-307), which is an insulin sensitizer that acts as a partial PPAR (peroxisome proliferator-activated receptor) gamma agonist. The study is the first in a series of planned Phase III trials which will investigate the safety and efficacy of Balaglitazone, as an oral anti-diabetic drug.

Back to news